🔴 Merck is trading 3.06% down today amid questions over melanoma-vaccine results

Merck is trading at $140.83, down 3.06%, as coverage linked its decline to earlier Phase 3 melanoma-vaccine data.

• The decline came despite positive sac-TMT endometrial-cancer results and FDA priority review announced October 26.
• Analysts questioned whether the melanoma-vaccine results met expectations and could apply beyond melanoma; coverage also linked selling in Moderna to the release.
• The broader market was higher; intraday volume was not available in the supplied price context or sources reviewed.